Caplin Steriles gets USFDA approval for Linezolid Injection

Regulatory product approvalBusiness Updates View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.7%Reaction day

₹1974.50

prior close

₹1907.20

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%-4.7% vs market

Pharmaceuticals peers, median of 156sector+0.7%-4.3% vs sector

On the reaction day the stock moved 4.7 pts less than Nifty Smallcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.1

15m

+0.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.7+1.0-4.7+0.7-4.3

Next day

-2.3+0.3-2.6+0.6-2.9

-1.0+0.9-1.9+1.1-2.2

-0.8+1.7-2.6+1.1-1.9

-0.9+2.1-3.0+1.0-1.9

-1.5+1.3-2.8+0.7-2.2

-3.0+0.4-3.5+0.2-3.2

15d

-7.1+3.5-10.6+1.1-8.1

-8.3+0.6-8.9-0.3-8.0

-10.8+0.9-11.7-3.3-7.4

-15.5-6.6-8.9-9.2-6.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Caplin Steriles, a subsidiary of Caplin Point Laboratories, has received final USFDA approval for its ANDA Linezolid Injection 600mg/300mL single-dose infusion bags, a generic equivalent of Pfizer's ZYVOX. Linezolid Injection had US sales of about $23 million for the 12-month period ending October 2025. Caplin Steriles now has 44 ANDA approvals out of 53 filed with the US FDA.

Likely market impact

Positive — new USFDA approval opens access to the US generic injectable market worth about $23 million annually.